Trials
MRD trials
The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov set of studies that are recruiting or not yet recruiting. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.
Recruiting and not-yet-recruiting studies that use ctDNA, cfDNA, or MRD in eligibility, a treatment decision, or a primary or secondary endpoint, plus observational studies focused on that testing. 1123 studies from 2267 registry records. Hematologic trials that list MRD only as a secondary endpoint are listed separately. Last synced Nov 18, 2026, 2:04 PM EST.
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Alliance for Clinical Trials in Oncology · 261 locations · Updated 2026-11-03
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
BeOne Medicines · 195 locations · Updated 2026-10-23
Chidamide Maintenance to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute T-Lymphoblastic Leukemia/Lymphoma
First Affiliated Hospital of Zhejiang University · Locations not reported · Updated 2026-08-19
A Study Comparing C Pola R-CHP+X With CR-CHOP in the Treatment of Previously Untreated DEL Under the Guidance of Genotyping
Ruijin Hospital · 1 locations · Updated 2026-04-06
Golidocitinib Versus Placebo as Maintenance Therapy for Peripheral T-Cell Lymphoma
Fudan University · 1 locations · Updated 2026-03-31
NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)
Health Institutes of Turkey · 4 locations · Updated 2026-03-30
Newly-diagnosed Pediatric T-cell ALL Protocol
Institute of Hematology & Blood Diseases Hospital, China · 27 locations · Updated 2025-08-26
Pirtobrutinib With Sonrotoclax and Rituximab for High-Risk Relapsed/Refractory Mantle-Cell Lymphoma Following Covalent BTK-Inhibitor Failure
Tianjin Medical University Cancer Institute and Hospital · 1 locations · Updated 2026-11-18
Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
Kerry Rogers · 1 locations · Updated 2026-11-09
MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma
University of Nebraska · 1 locations · Updated 2026-11-06
Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
City of Hope Medical Center · 2 locations · Updated 2026-11-06
A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell Lymphoma
Memorial Sloan Kettering Cancer Center · 7 locations · Updated 2026-11-04
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
Allogene Therapeutics · 86 locations · Updated 2026-10-30
Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Mayo Clinic · 3 locations · Updated 2026-10-26
Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial
Fred Hutchinson Cancer Center · 1 locations · Updated 2026-10-23
Tacabrutideg and Sonrotoclax, With Response-Guided Obinutuzumab, for the Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Fred Hutchinson Cancer Center · 1 locations · Updated 2026-10-21
ctDNA-Guided Therapy for Relapsed/Refractory Hodgkin Lymphoma
Michael Spinner, MD · 6 locations · Updated 2026-10-20
Nemtabrutinib and Venetoclax for the Treatment of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Jennifer Woyach · 1 locations · Updated 2026-10-15
A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
University of Rochester · 1 locations · Updated 2026-10-13
Venetoclax Treatment (26 Cycles) With 6 Cycles or 12 Cycles of Epcoritamab in Patients With Relapsed or Refractory CLL or SLL
Stichting Hemato-Oncologie voor Volwassenen Nederland · 29 locations · Updated 2026-10-05
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex)
Allotera Therapeutics · 18 locations · Updated 2026-09-28
UCD19 CarT in Treatment of Pediatric B-ALL and B-NHL
University of Colorado, Denver · 1 locations · Updated 2026-09-14
Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
M.D. Anderson Cancer Center · 1 locations · Updated 2026-09-10
Personalized Reduction of Chemotherapy Intensity Through ctDNA Evaluation for the Treatment of Patients With Advanced Hodgkin Lymphoma
University of Washington · 6 locations · Updated 2026-09-09
A Study of CTD402 in T-ALL/LBL Patients
Imviva Bio · 9 locations · Updated 2026-08-19
Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLL
Massachusetts General Hospital · 2 locations · Updated 2026-08-11
Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)
St. Jude Children's Research Hospital · 4 locations · Updated 2026-08-10
Pirtobrutinib+Sonrotoclax(PS) Regimen in the Treatment of B-Cell Lymphoma
Changzhou No.2 People's Hospital · 1 locations · Updated 2026-08-06
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations
The Lymphoma Academic Research Organisation · 29 locations · Updated 2026-07-31
A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies
Guangzhou Lupeng Pharmaceutical Company LTD. · 1 locations · Updated 2026-07-30
Therapy for Newly Diagnosed Patients With B-Cell Precursor Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital · 3 locations · Updated 2026-07-16
Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma
M.D. Anderson Cancer Center · 1 locations · Updated 2026-06-30
A Study of MRD-Guided Zanubrutinib Plus Sonrotoclax in Treatment-Naïve, High-Risk CLL/SLL Patients
The First Affiliated Hospital with Nanjing Medical University · 1 locations · Updated 2026-06-26
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
Masonic Cancer Center, University of Minnesota · 1 locations · Updated 2026-06-25
Zanubrutinib With Obinutuzumab in Untreated Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
PETHEMA Foundation · 19 locations · Updated 2026-06-25
Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete Remission
Rong Tao · 1 locations · Updated 2026-06-18
Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)
Jennifer Amengual · 2 locations · Updated 2026-05-27
Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)
Stephan Grupp MD PhD · 1 locations · Updated 2026-05-26
Cord Blood Transplantation in Children and Young Adults With Blood Cancer
Memorial Sloan Kettering Cancer Center · 1 locations · Updated 2026-05-14
Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma
Fred Hutchinson Cancer Center · 1 locations · Updated 2026-05-11
Showing 1–40 of 110. Older studies
More hematologic trials (68) that list MRD only as a secondary endpoint
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Merck Sharp & Dohme LLC · 107 locations · Updated 2026-11-17
A Clinical Trial of MK-1045 With Zilovertamab Vedotin in Participants With Diffuse Large B-cell Lymphoma (MK-1045-010)
Merck Sharp & Dohme LLC · Locations not reported · Updated 2026-11-05
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma
Regeneron Pharmaceuticals · 195 locations · Updated 2026-11-04
Comparison Between Local Radiotherapy Alone or Combined With Obinutuzumab in Early Stage Follicular Lymphoma: the GAZEBO Trial From the Fondazione Italiana Linfomi
Fondazione Italiana Linfomi - ETS · 49 locations · Updated 2026-09-08
A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.
Ascentage Pharma Group Inc. · 10 locations · Updated 2026-07-28
A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)
Celgene · 160 locations · Updated 2026-05-20
International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma
University Hospital Muenster · 228 locations · Updated 2026-05-06
A Phase 2 Study of Epcoritamab in Patients With Follicular Lymphoma and Marginal Zone Lymphoma Not Accomplishing a Complete Response With Upfront Therapy
Beth Israel Deaconess Medical Center · 3 locations · Updated 2026-11-12
Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma
City of Hope Medical Center · 1 locations · Updated 2026-11-03
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
VA Office of Research and Development · 4 locations · Updated 2026-10-30
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
City of Hope Medical Center · 3 locations · Updated 2026-10-26
MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without Obinutuzumab
AstraZeneca · 47 locations · Updated 2026-10-23
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
AstraZeneca · 94 locations · Updated 2026-10-14
Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
City of Hope Medical Center · 8 locations · Updated 2026-10-13
Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
University of California, San Francisco · 4 locations · Updated 2026-10-01
Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell Lymphoma
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea · 19 locations · Updated 2026-09-29
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
BeOne Medicines · 49 locations · Updated 2026-09-11
Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 Trial
City of Hope Medical Center · 3 locations · Updated 2026-09-10
TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma
Brown University · 1 locations · Updated 2026-09-01
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
AvenCell Therapeutics, Inc. · 13 locations · Updated 2026-08-28
Mosunetuzumab and Polatuzumab Vedotin With Split-Dose CHP Chemotherapy for Elderly Patients With Diffuse Large B-Cell Lymphoma
Medical College of Wisconsin · 1 locations · Updated 2026-08-25
GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid Tumors
Vitruviae · Locations not reported · Updated 2026-08-06
Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors
UNC Lineberger Comprehensive Cancer Center · 1 locations · Updated 2026-08-05
Efficacy and Safety of Lisaftoclax (APG-2575) Monotherapy in Patients With Mature B-cell Lymphoma
Henan Cancer Hospital · 1 locations · Updated 2026-07-29
A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)
Beijing InnoCare Pharma Tech Co., Ltd. · 29 locations · Updated 2026-07-23
Orelabrutinib Combined With Obinutuzumab and Short-Course Venetoclax in Patients With Treatment-Naïve Mantle Cell Lymphoma (MCL)
The First Affiliated Hospital with Nanjing Medical University · 2 locations · Updated 2026-07-22
Phase II Study of Glofitamab With Venetoclax +/- Zanubrutinib in High-risk Mantle-cell Lymphoma
The Lymphoma Academic Research Organisation · 16 locations · Updated 2026-07-10
Odronextamab for the Treatment of Relapsed and Refractory Diffuse Large B-cell Lymphoma Before and After Chimeric Antigen Receptor T-cell Therapy
University of California, Davis · 1 locations · Updated 2026-07-08
Lisaftoclax Plus Pirtobrutinib in Relapsed or Refractory Mantle Cell Lymphoma After BTK-Targeted Therapy
Henan Cancer Hospital · 1 locations · Updated 2026-07-06
Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma
University of California, Davis · 1 locations · Updated 2026-06-30
Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center · 1 locations · Updated 2026-05-20
Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies
Beijing Biotech · 1 locations · Updated 2026-04-13
Co-administration of CART22-65s and huCART19 for B-ALL
Stephan Grupp MD PhD · 1 locations · Updated 2026-03-27
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
Jennifer Crombie, MD · 3 locations · Updated 2026-03-05
Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL
Zulfa Omer · 1 locations · Updated 2026-01-06
CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL).
Lazaros Lekakis · 1 locations · Updated 2025-12-31
Zanubrutinib, Obinutuzumab, and Lenalidomide (ZGR) in the Treatment of Newly Diagnosed Splenic B-cell Lymphoma With Prominent Nucleoli (SBLPN): A Prospective, Open-label, Single-arm Clinical Trial
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2025-12-18
SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2025-12-15
LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This
Zulfa Omer · 1 locations · Updated 2025-08-14
Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Ruijin Hospital · 1 locations · Updated 2025-08-14
Clinical Study of the Safety and Efficacy of ASCT Combined With CD7-CART in the Treatment of CD7+ TCL
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2025-08-06
The PACMAN-Hu19 Trial: a Study of the Safety and Feasibility of Locally Produced, CD19-targeted and Human CAR T-cell Therapy in Children and Young Adults With Relapsed or Refractory B-cell Malignancies
Princess Maxima Center for Pediatric Oncology · 2 locations · Updated 2025-06-13
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
John Lister · 1 locations · Updated 2025-01-13
VHAG in Treating R/R T-ALL/LBL
First Affiliated Hospital of Zhejiang University · 1 locations · Updated 2024-12-19
This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell Lymphoma
Henan Cancer Hospital · Locations not reported · Updated 2024-05-23
A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Mantle CellLymphoma Patients
Shanxi Province Cancer Hospital · 1 locations · Updated 2024-02-13
A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
Australasian Leukaemia and Lymphoma Group · 2 locations · Updated 2024-01-08
Clinical Study of XPO1 Inhibitor Selinexor Combined With COPL in Newly Diagnosed Advanced NK/T-cell Lymphoma
Chinese PLA General Hospital · 1 locations · Updated 2023-04-27
A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)
Autolus Limited · 15 locations · Updated 2026-11-13
CLIC-2201 for the Treatment of Relapsed/Refractory B Cell Malignancies
British Columbia Cancer Agency · 7 locations · Updated 2026-10-14
U69-CART-Cells For R/R T-ALL
The First Affiliated Hospital of Soochow University · 1 locations · Updated 2026-09-02
First-in-human Study of a New Treatment (4A10) for Patients With Relapsed or Hard-to-treat Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, Focused on Safety and How the Drug Behaves in the Body and Early Signs of Effect.
Allterum Therapeutics, Inc · 7 locations · Updated 2026-09-01
Long-term Follow up Local Registry Study of Kymriah in South Korea
Novartis Pharmaceuticals · 18 locations · Updated 2026-07-30
An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · 1 locations · Updated 2026-07-21
GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma
Chinese PLA General Hospital · 1 locations · Updated 2026-06-26
CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies
Mayo Clinic · 1 locations · Updated 2026-06-09
Evaluation of the Safety and Efficacy of Sup19 CAR-T Cells in Patients With Previously Failed CD19-Targeted Therapy or CD19-Weakly Expressed Hematologic Tumors
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2026-04-20
Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial
Fondazione Italiana Linfomi - ETS · 26 locations · Updated 2025-12-29
Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)
University Hospital, Basel, Switzerland · 1 locations · Updated 2025-12-24
Precision Physical Exercise for Personalized Onco-Hematology.
University of Salamanca · Locations not reported · Updated 2025-12-16
A Clinical Study to Explore CT1195E in Patients With Relapsed/Refractory B-Cell Neoplasms
Institute of Hematology & Blood Diseases Hospital, China · 1 locations · Updated 2025-11-18
Tumor Molecular Profiling in Early Phase Clinical Trials
Oncology Institute of Southern Switzerland · 1 locations · Updated 2025-11-18
Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma
The First Affiliated Hospital with Nanjing Medical University · 1 locations · Updated 2025-08-17
CD-19 CAR-T Cell for Pediatric ALL or Lymphoma
Hong Kong Children's Hospital · 1 locations · Updated 2025-03-10
Immunological Senescence Phenotype as a Resistance Profile to Pembrolizumab in Patients With Relapsed/Refractory Hodgkin's Lymphoma
IRCCS Azienda Ospedaliero-Universitaria di Bologna · 1 locations · Updated 2024-12-13
Evaluation of the KIR3DL2 Marker in Flow Cytometry for Sézary Syndrome Diagnosis, Therapeutic Response and Residual Disease: a Prospective and Multicenter Study
Assistance Publique - Hôpitaux de Paris · Locations not reported · Updated 2024-10-21
B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021
Federal Research Institute of Pediatric Hematology, Oncology and Immunology · 1 locations · Updated 2022-08-26
A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy
He Huang · 1 locations · Updated 2020-12-28
Status can change after this sync. The curated list is the other view on this page. Evidence holds the published results.